Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
Open Access
- 11 January 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1299792
Abstract
Patients with coronavirus disease-2019 (COVID-19) have an increased risk of thrombosis and acute respiratory distress syndrome (ARDS). Thrombosis is often attributed to increases in plasminogen activator inhibitor-1 (PAI-1) and a shut-down of fibrinolysis (blood clot dissolution). Decreased urokinase-type plasminogen activator (uPA), a protease necessary for cell-associated plasmin generation, and increased tissue-type plasminogen activator (tPA) and PAI-1 levels have been reported in COVID-19 patients. Because these factors can occur in free and complexed forms with differences in their biological functions, we examined the predictive impact of uPA, tPA, and PAI-1 in their free forms and complexes as a biomarker for COVID-19 severity and the development of ARDS. In this retrospective study of 69 Japanese adults hospitalized with COVID-19 and 20 healthy donors, we found elevated free, non-complexed PAI-1 antigen, low circulating uPA, and uPA/PAI-1 but not tPA/PAI-1 complex levels to be associated with COVID-19 severity and ARDS development. This biomarker profile was typical for patients in the complicated phase. Lack of PAI-1 activity in circulation despite free, non-complexed PAI-1 protein and plasmin/α2anti-plasmin complex correlated with suPAR and sVCAM levels, markers indicating endothelial dysfunction. Furthermore, uPA/PAI-1 complex levels positively correlated with TNFα, a cytokine reported to trigger inflammatory cell death and tissue damage. Those levels also positively correlated with lymphopenia and the pro-inflammatory factors interleukin1β (IL1β), IL6, and C-reactive protein, markers associated with the anti-viral inflammatory response. These findings argue for using uPA and uPA/PAI-1 as novel biomarkers to detect patients at risk of developing severe COVID-19, including ARDS.Keywords
Funding Information
- Japan Society for the Promotion of Science (MEXT)
This publication has 66 references indexed in Scilit:
- PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in miceThorax, 2011
- Prognostic significance of urokinase-type plasminogen activator and its receptor in patients with systemic inflammatory response syndromeWorld Journal of Emergency Medicine, 2011
- Plasma concentrations of VCAM‐1 and PAI‐1: A predictive biomarker for post‐operative recurrence in colorectal cancerCancer Science, 2010
- The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signalingFEBS Letters, 2009
- Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patientsExperimental Hematology, 2008
- Increased soluble urokinase plasminogen activator receptor (suPAR) serum levels after granulocyte colony-stimulating factor treatment do not predict successful progenitor cell mobilization in vivoBlood, 2006
- Induction of PAI‐1 expression by tumor necrosis factor α in endothelial cells is mediated by its responsive element located in the 4G/5G siteThe FEBS Journal, 2005
- The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP projectThrombosis Research, 2005
- Inflammation and thrombosisJournal of Thrombosis and Haemostasis, 2003
- Depressed Bronchoalveolar Urokinase Activity in Patients with Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1990